AbCellera Biologics Inc. (NASDAQ:ABCL) currently has a daily average trading volume of 1.73M but it saw 1268952 shares traded on Thursday. With a market cap of 2.24B USD, stock’s current market price of $7.48 came rising about 0.67 while comparing to the previous closing price of $7.43. In past 52 weeks, the stock remained buoying in the range of price level as high as $14.97 and as low as $5.42. In the recent trading on the day, stock has struck highest price mark of $7.52 while lowest mark touched by it was $7.215.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Taking a look at 20-day trading activity of AbCellera Biologics Inc. (ABCL) gives us an average price of $8.24, while its current price level is -50.03% below from 52-week high level whereas it is 38.01% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.43 while that of 200 days or SMA-200 reads an average of $10.55. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.97% during that period while stretching the period over a month that decreases to 4.63%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.42 which implies that the stock is in oversold territory.
Truist also issued its recommendations for the stock as it initiated the price target for the stock is $29.
Over the week, ABCL’s stock price is moving -4.96% down while it is -24.97% when we observe its performance for the past one month. Year-to-date it is -26.16% down and over the past year, the stock is showing a downside performance of -3.73%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of $0.08 beat the consensus estimate of $0.04 for the same. For ABCL, analysts are forecasting an EPS-growth rate of 33.30% for current year and estimate for EPS growth in next year is -170.30%. In next quarter, company is expected to be making quarterly sales of $14.76 million as analysts are expecting the sales for current fiscal year at $517.63 million and seeing the company making $107.65 million in sales next year. Moreover, analysts are in estimates of $50.8 million for current-quarter revenue.
Currently, AbCellera Biologics Inc.’s total number of outstanding shares is 286.31M with 28.78% of that held by the insiders while 50.38% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 11.00% and return on equity (ROE) at 12.90%. It has a price to earnings ratio (P/E ratio) of 15.05. Stock has a price to book (P/B) ratio of 1.74 while price to sale or P/S ratio amounts to 4.62. Its return on asset (ROA) is 10.10% on average.
In the most recent quarter, SMDAM Global AI Equity Mother Fun came cutting its stake by -2.57% in the company and now holds 4.72 million or 1.64% of the company’s stake having worth of about 39.68 million.
